Recombinant Mouse Developmental pluripotency-associated protein 5B/5C (Dppa5b)

What is Dppa5 and what are its known functions in stem cell biology?

Dppa5 (Developmental pluripotency-associated 5), also known as ESG1, is an RNA binding protein highly expressed in undifferentiated pluripotent stem cells . Its primary functions include:

• Maintenance of embryonic stem cell pluripotency

• Regulation of hematopoietic stem cell (HSC) activity

• Suppression of endoplasmic reticulum (ER) stress

• Association with specific target mRNAs for post-transcriptional regulation

• Support of cellular reprogramming processes

While Dppa5 is important for pluripotency maintenance, research indicates it is dispensable for self-renewal of pluripotent ES cells and establishment of germ cells .

What is the molecular structure and key characteristics of recombinant mouse Dppa5 protein?

Recombinant mouse Dppa5 protein has the following characteristics:

The recombinant protein typically includes a C-terminal tag to facilitate purification and detection in experimental settings .

What are the optimal storage and handling conditions for recombinant Dppa5?

For maximum stability and activity of recombinant Dppa5 protein:

• Store at -80°C after receiving vials

• Avoid repeated freeze-thaw cycles as they can compromise protein integrity

• For testing in cell culture applications, filter before use (note that some protein loss may occur during filtration)

• Reconstitute lyophilized protein at approximately 200 μg/mL in buffer with controlled pH (similar to protocols for other recombinant proteins)

• When stored properly, the protein remains stable for approximately 12 months from date of receipt

How can I verify the activity of recombinant Dppa5 protein in experimental settings?

Functional verification of recombinant Dppa5 can be accomplished through:

• Protein-protein interaction assays: Co-immunoprecipitation experiments to confirm interaction with known binding partners, particularly NANOG

• RNA binding assays: RNA immunoprecipitation followed by sequencing (RIP-seq) to identify bound RNA targets

• Cellular assays:

  • Measuring impact on NANOG protein stability in pluripotent stem cells

  • Assessing changes in ER stress markers when overexpressed in hematopoietic stem cells

  • Evaluating enhancement of reprogramming efficiency when added to somatic cell reprogramming protocols

• Western blot analysis: Using tag-specific antibodies to confirm protein expression and integrity

What mechanisms underlie Dppa5's role in regulating endoplasmic reticulum stress in hematopoietic stem cells?

Dppa5 has been identified as a critical regulator of ER stress in hematopoietic stem cells (HSCs). The mechanism involves:

• Reduction of ER stress markers: Ectopic expression of Dppa5 suppresses ER stress markers in HSCs

• Improved reconstitution capacity: HSCs with Dppa5 overexpression show robustly increased reconstitution levels after bone marrow transplantation through suppression of ER stress and apoptosis

• Physiological necessity: Knockdown experiments demonstrate that Dppa5 depletion impairs long-term reconstitution ability of HSCs due to elevated ER stress levels, confirming the physiological importance of this pathway

• Chemical chaperone effects: Notably, chemical chaperones that decrease ER stress in HSCs also increase HSC engraftment, suggesting a generalizable principle

This represents a pivotal connection between ER stress regulation and stem cell properties in HSCs, with significant implications for ex vivo HSC manipulation for clinical applications .

How does Dppa5 stabilize NANOG protein, and what are the implications for pluripotency maintenance?

Dppa5 regulates NANOG through post-transcriptional mechanisms:

• Direct physical interaction: Coimmunoprecipitation experiments demonstrate that Dppa5 directly interacts with NANOG protein

• Protein stabilization: Dppa5 increases NANOG protein levels without affecting mRNA levels, suggesting a post-transcriptional mechanism

• Enhanced NANOG function: The stabilization of NANOG by Dppa5 enhances the regulatory effects of NANOG on target genes, including SALL4, a transcription factor required for ESC pluripotency

• Feeder-free culture relevance: Human PSCs cultured on feeder-free substrates (including Matrigel, Laminin-511, Vitronectin, or synthetic polymers) show significantly higher DPPA5 expression compared to cells grown on mouse embryonic fibroblasts, suggesting substrate-dependent regulation

The DPPA5-NANOG interaction represents an important regulatory mechanism for maintaining pluripotency in stem cells, particularly under feeder-free culture conditions that are increasingly important for clinical applications .

What are the experimental approaches for studying the impact of Dppa5 on cellular reprogramming efficiency?

Researchers investigating Dppa5's role in reprogramming can employ these methods:

• Overexpression experiments:

  • Introduce Dppa5 expression vectors into somatic cells along with standard reprogramming factors (e.g., OCT4, SOX2, KLF4, c-MYC)

  • Quantify reprogramming efficiency by counting colonies expressing pluripotency markers (e.g., alkaline phosphatase, SSEA-4, TRA-1-60)

  • Compare temporal dynamics of reprogramming with and without Dppa5 enhancement

• Mechanistic studies:

  • Analyze NANOG protein levels during reprogramming with and without Dppa5 overexpression

  • Perform pulse-chase experiments to determine NANOG protein half-life

  • Use proteasome inhibitors to test whether Dppa5 protects NANOG from proteasomal degradation

• RNA-binding partner identification:

  • Employ CLIP-seq (crosslinking immunoprecipitation followed by sequencing) to identify RNA targets of Dppa5 during reprogramming

  • Validate whether these interactions affect translation efficiency or mRNA stability of factors important for reprogramming

• Knockdown/knockout experiments:

  • Use siRNA or CRISPR-Cas9 to reduce or eliminate Dppa5 expression during reprogramming

  • Assess whether reprogramming efficiency decreases and whether this can be rescued by NANOG overexpression

How can the specific RNA targets of Dppa5 be identified and validated in stem cell contexts?

Identifying RNA targets of Dppa5 requires specialized techniques:

• CLIP-seq approaches:

  • Perform UV crosslinking to stabilize RNA-protein interactions

  • Immunoprecipitate Dppa5 using tag-specific antibodies or Dppa5-specific antibodies

  • Sequence the bound RNA fragments to identify binding sites at nucleotide resolution

• RIP-seq (RNA immunoprecipitation followed by sequencing):

  • Immunoprecipitate Dppa5 under native conditions

  • Extract and sequence associated RNAs

  • Compare to control immunoprecipitation to identify specific targets

• Validation methods:

  • RNA electrophoretic mobility shift assay (EMSA) to confirm direct binding

  • Reporter assays with wild-type and mutated binding sites to assess functional importance

  • Analysis of target RNA levels, stability, and translation efficiency in Dppa5 knockout/knockdown contexts

• Identification of binding motifs:

  • Bioinformatic analysis of identified binding sites to derive consensus binding motifs

  • Validation of these motifs through mutational analysis

This approach can reveal how Dppa5 regulates specific mRNAs to maintain pluripotency and support reprogramming.

What is known about the functional differences between Dppa5 paralogs and their evolutionary significance?

The study of Dppa5 paralogs remains an area requiring further research:

• Limited paralog-specific data: While mouse Dppa5 (also known as Dppa5a) has been well-characterized, less information is available regarding the specific functions of Dppa5b and Dppa5c

• Evolutionary considerations:

  • The Dppa5 gene family has undergone species-specific duplications

  • These paralogs likely arose through gene duplication events and may have evolved specialized functions

  • Comparative analysis across species can provide insights into conserved versus divergent functions

• Experimental approaches for paralog differentiation:

  • Paralog-specific knockdown or knockout studies

  • Complementation experiments to test functional redundancy

  • Domain swapping to identify regions responsible for paralog-specific functions

• Expression analysis:

  • Studies examining the expression patterns of different Dppa5 paralogs across developmental stages and tissues can reveal specialized roles

  • Single-cell RNA sequencing can identify cells expressing specific paralogs

Further research is needed to elucidate the potentially distinct roles of Dppa5 paralogs in pluripotency, differentiation, and reprogramming contexts.

What are the best experimental models for studying Dppa5 function in development and stemness?

Several experimental models provide valuable insights into Dppa5 function:

• Mouse embryonic stem cells (mESCs):

  • Express high levels of endogenous Dppa5

  • Allow for genetic manipulation through CRISPR-Cas9 or siRNA approaches

  • Differentiation protocols can assess the impact of Dppa5 modulation on lineage commitment

• Induced pluripotent stem cells (iPSCs):

  • Reprogramming models to study Dppa5's role in the acquisition of pluripotency

  • Both human and mouse systems show conservation of Dppa5 function

• Hematopoietic stem cells (HSCs):

  • Critical model for studying Dppa5's role in adult stem cell maintenance and function

  • Allow for in vivo reconstitution assays to assess functional outcomes of Dppa5 modulation

• Transgenic mouse models:

  • Conditional knockout models to study tissue-specific or developmental stage-specific requirements

  • Overexpression models to assess gain-of-function phenotypes

• In vitro differentiation systems:

  • Cardiogenic differentiation protocols similar to those used in patient-derived iPSC studies

  • Neural differentiation to examine lineage-specific effects

What are the technical considerations for using recombinant Dppa5 protein in cell culture experiments?

When utilizing recombinant Dppa5 protein in cell culture:

• Protein delivery methods:

  • Direct addition to culture medium (limited by cellular uptake)

  • Protein transfection reagents (e.g., Chariot, ProDeliverIN)

  • Cell-penetrating peptide tags to facilitate uptake

  • Microinjection for single-cell applications

• Concentration optimization:

  • Titration experiments to determine effective doses

  • Typical starting range: 100-500 ng/mL, based on protocols for similar recombinant factors

  • Cell viability assessments to identify potential toxic effects at high concentrations

• Activity verification:

  • Positive controls such as known effects on NANOG stability or ER stress markers

  • Time-course experiments to determine optimal treatment duration

  • Combination with other factors to assess synergistic effects

• Experimental controls:

  • Heat-inactivated protein controls

  • Tag-only protein controls when using tagged recombinant proteins

  • Vehicle controls matching the buffer composition

• Pre-treatment considerations:

  • Filter sterilize using 0.2 μm filters before addition to cell culture

  • Account for protein loss during filtration by quantifying protein pre- and post-filtration

How can I establish a knockdown/knockout system to study Dppa5 loss-of-function?

For effective Dppa5 loss-of-function studies:

• siRNA/shRNA approaches:

  • Design multiple siRNA sequences targeting different regions of Dppa5 mRNA

  • For longer-term studies, use shRNA expressed from lentiviral vectors

  • Validate knockdown efficiency at both mRNA and protein levels

  • This approach has been successfully used in HSC studies to demonstrate the importance of Dppa5 in long-term reconstitution ability

• CRISPR-Cas9 knockout strategies:

  • Design guide RNAs targeting early exons of Dppa5

  • Consider using paired guides for complete gene deletion

  • Screen for successful knockouts by DNA sequencing, Western blot, and functional assays

  • Create conditional knockouts (floxed alleles with inducible Cre) for temporal control

• Validation approaches:

  • Rescue experiments with wild-type or mutant versions to confirm specificity

  • Assessment of known downstream effects (e.g., NANOG stability, ER stress levels)

  • Comparative analysis with published phenotypes

• Consideration of redundancy:

  • In systems with multiple Dppa5 paralogs, consider simultaneous targeting to overcome potential functional redundancy

  • Use of degron tags for inducible protein degradation as an alternative approach

What approaches can be used to investigate the interaction between Dppa5 and NANOG?

To study the Dppa5-NANOG interaction:

• Co-immunoprecipitation (Co-IP):

  • Use tag-specific antibodies to pull down tagged Dppa5 and detect NANOG

  • Perform reciprocal experiments pulling down NANOG to detect Dppa5

  • Include RNase treatment to determine if the interaction is RNA-dependent

• Protein stability assays:

  • Perform cycloheximide chase experiments to measure NANOG half-life in the presence or absence of Dppa5

  • Use proteasome inhibitors (e.g., MG132) to determine if Dppa5 protects NANOG from proteasomal degradation

• Protein domain mapping:

  • Generate truncated versions of both proteins to identify interaction domains

  • Use site-directed mutagenesis to identify critical residues for interaction

  • Employ peptide arrays to map minimal interaction sequences

• Proximity labeling techniques:

  • BioID or TurboID fusions to Dppa5 to identify proximal proteins in living cells

  • APEX2 labeling for temporally controlled proximity labeling

• Functional readouts:

  • Reporter assays with NANOG-responsive elements to assess functional enhancement

  • Quantitative RT-PCR of NANOG target genes (e.g., SALL4) to measure enhanced NANOG function

What are common challenges in producing and purifying active recombinant Dppa5 protein?

Researchers may encounter these challenges:

• Expression system selection:

  • HEK293T cells are commonly used for mammalian expression

  • E. coli systems may require refolding steps to obtain active protein

  • Insect cell systems may provide intermediate complexity post-translational modifications

• Solubility issues:

  • Dppa5 may form inclusion bodies in bacterial expression systems

  • Optimization of induction conditions (temperature, inducer concentration, duration)

  • Use of solubility tags (e.g., MBP, SUMO) may improve soluble expression

• Purification challenges:

  • Multiple purification steps may be needed to achieve >80% purity

  • Affinity chromatography using the C-terminal tag (e.g., DDK/FLAG tag) provides initial enrichment

  • Size exclusion chromatography to remove aggregates and truncated products

  • Ion exchange chromatography for final polishing

• Activity preservation:

  • Buffer optimization to maintain native conformation

  • Addition of stabilizers like glycerol (typically 10%) to prevent aggregation

  • Avoiding detergents that may interfere with protein-protein or protein-RNA interactions

• Quality control:

  • SDS-PAGE and Coomassie blue staining to assess purity (target >80%)

  • Mass spectrometry to confirm identity

  • Functional assays to verify activity after purification

How can I interpret contradictory data regarding Dppa5 function in different stem cell contexts?

When facing contradictory results:

• Context-dependent functions:

  • Dppa5 may have different roles in embryonic stem cells versus adult stem cells

  • Compare experimental conditions, including culture systems (feeder vs. feeder-free)

  • Consider species differences (mouse vs. human DPPA5)

• Expression level considerations:

  • Overexpression may yield different phenotypes than physiological expression

  • Knockdown efficiency may vary between studies

  • Quantify expression levels when comparing across studies

• Redundancy mechanisms:

  • Other factors may compensate for Dppa5 loss in some contexts

  • Consider parallel pathways regulating similar processes

  • Investigate the expression of related family members that may compensate

• Technical differences:

  • Antibody specificity issues may lead to discrepant results

  • Cell line authentication to ensure consistent genetic background

  • Passage number effects in cultured stem cells

• Resolution strategies:

  • Perform side-by-side comparisons under identical conditions

  • Use multiple complementary approaches to validate findings

  • Collaboration with labs reporting different results to identify sources of variation

What are the best approaches for measuring changes in ER stress when studying Dppa5 function in HSCs?

Accurate measurement of ER stress in HSCs requires:

• Gene expression markers:

  • qRT-PCR for canonical ER stress genes: BiP/GRP78, CHOP, XBP1 (spliced vs. unspliced ratio)

  • RNA-seq for comprehensive analysis of the ER stress transcriptional response

  • Consider pathway analysis to distinguish between different branches of the unfolded protein response (UPR)

• Protein-level markers:

  • Western blot for BiP/GRP78, phosphorylated eIF2α, ATF4, and CHOP

  • Immunofluorescence to assess subcellular localization of UPR sensors

  • Flow cytometry for intracellular staining of ER stress markers in rare HSC populations

• Functional assays:

  • ER stress inducers (tunicamycin, thapsigargin) as positive controls

  • Chemical chaperones (TUDCA, 4-PBA) as negative controls or for rescue experiments

  • Cell viability and apoptosis assays to connect ER stress to functional outcomes

• Single-cell approaches:

  • Single-cell RNA-seq to capture heterogeneity in the HSC response

  • ER stress reporter systems (e.g., XBP1 splicing reporters) compatible with flow cytometry

• In vivo assessment:

  • Bone marrow transplantation experiments with Dppa5-modulated HSCs to connect ER stress changes to functional reconstitution capacity

  • Analysis of HSC homing, survival, and proliferation post-transplantation

What controls should be included when performing RNA-binding studies with recombinant Dppa5?

Essential controls for RNA-binding experiments include:

• Negative controls:

  • Non-specific RNA binding proteins (e.g., BSA) to establish background binding

  • RNA samples not expected to interact with Dppa5

  • Mutated versions of Dppa5 with disrupted RNA-binding domains

• Binding specificity controls:

  • Competition assays with unlabeled RNA to demonstrate specific binding

  • Comparison of binding to random RNA sequences versus potential targets

  • RNase treatment controls to confirm RNA-dependence of observed interactions

• Technical controls:

  • Input samples to normalize for RNA abundance differences

  • Mock immunoprecipitation controls using non-specific antibodies or pre-immune serum

  • Demonstration of consistent RNA integrity throughout the experiment

• Validation approaches:

  • Secondary binding assays using different methodologies (e.g., EMSA following RIP)

  • In vivo crosslinking to capture physiologically relevant interactions

  • Functional studies to demonstrate the consequence of Dppa5-RNA binding

• Computational analysis controls:

  • Use of appropriate statistical methods for peak calling in CLIP-seq data

  • Multiple biological replicates to ensure reproducibility

  • Comparison with published RNA-binding motifs or datasets

What are the promising therapeutic applications of understanding Dppa5 function?

Understanding Dppa5 function may lead to several therapeutic applications:

• Ex vivo HSC expansion:

  • Manipulation of Dppa5 expression or activity to reduce ER stress and improve HSC survival during ex vivo manipulation

  • Development of small molecules mimicking Dppa5's protective effects on HSCs

  • Potential application in bone marrow transplantation protocols

• Enhanced cellular reprogramming:

  • Incorporation of Dppa5 into reprogramming protocols to increase efficiency

  • Optimization of feeder-free culture systems leveraging Dppa5's role in pluripotency maintenance

  • Generation of more stable iPSCs for regenerative medicine applications

• Cardiomyocyte development:

  • Based on studies of congenital heart defects, Dppa5 manipulation might influence cardiac development pathways

  • Potential application in directing differentiation of stem cells into cardiac lineages

• ER stress modulation:

  • Identification of Dppa5-regulated pathways may reveal new targets for treating diseases associated with ER stress

  • Applications in conditions where stem cell function is compromised by elevated ER stress

• RNA-based therapeutics:

  • Understanding Dppa5's RNA-binding properties may inform the development of RNA-based therapeutic approaches

  • Targeting specific RNA species identified as Dppa5 partners

What technological advances would facilitate better understanding of Dppa5 structure-function relationships?

Advancing Dppa5 research would benefit from:

• Structural biology approaches:

  • High-resolution crystal or cryo-EM structures of Dppa5 alone and in complex with RNA targets

  • NMR studies to understand the dynamics of Dppa5-RNA interactions

  • Computational modeling of RNA recognition by Dppa5

• Advanced protein engineering:

  • Development of Dppa5 variants with enhanced stability or activity

  • Domain swap experiments to create chimeric proteins with novel properties

  • Optogenetic or chemically inducible Dppa5 variants for temporal control of activity

• Single-molecule techniques:

  • FRET-based assays to study Dppa5-RNA binding dynamics in real-time

  • Single-molecule pull-down assays to characterize the stoichiometry of Dppa5 complexes

  • Super-resolution microscopy to visualize Dppa5 localization and dynamics in live cells

• High-throughput screening approaches:

  • Development of reporter systems to identify compounds modulating Dppa5 activity

  • CRISPR screens to identify genetic modifiers of Dppa5 function

  • Proteomic approaches to comprehensively map the Dppa5 interactome

• Integrative multi-omics:

  • Combined analysis of transcriptomics, proteomics, and functional genomics data

  • Single-cell multi-omics to understand Dppa5 function in heterogeneous stem cell populations